Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures - Slideshow

Xenon Pharmaceuticals announced positive Phase 3 results for azetukalner, its investigational drug for focal onset seizures, meeting primary endpoints in the X-TOLE2 study. The trial demonstrated statistically significant seizure reduction versus placebo, reinforcing azetukalner’s potential as a novel epilepsy treatment with a favorable safety profile. Data from X-TOLE2, released in March 2026, builds on prior Phase 2 success, positioning the drug for potential regulatory submission and commercialization. The company highlighted azetukalner’s mechanism targeting Kv7 potassium channels, a novel approach distinct from existing antiseizure medications. Investor and clinical interest is expected to rise as Xenon prepares to present detailed findings at upcoming medical conferences.